Release date: 2024-08-28 11:37:20 Article From: Lucius Laos Recommended: 173
Balversa is an oral anti-cancer drug mainly used for the treatment of advanced or metastatic urothelial carcinoma with FGFR2/3 mutations, which shows anti-tumor potential by inhibiting the activity of FGFR protein to prevent tumor cell proliferation and spread.
As a drug for the treatment of specific types of cancer, the use of Balversa requires special attention to the following two points:
Balversa is effective for cancer patients with specific gene mutations, and it is important to perform genetic testing before use to ensure that the patient is eligible for medication. At the same time, patients should strictly follow the doctor's medication instructions, including dosage, administration mode, and medication cycle, to ensure the effect of treatment and reduce potential risks.
Balversa may cause a range of adverse effects, and any discomfort or suspected adverse reactions should be reported to your doctor immediately. Depending on the patient's condition, the doctor will adjust the treatment plan or take appropriate measures to reduce the adverse effects.
After understanding the significant efficacy of Balversa, we need to pay attention to the precautions for its use, especially the changes in vision, such as blurred vision, flashes of light, and other visual problems during use, we should seek medical evaluation in time.
Patients may experience vision-related problems with Balversa with specific symptoms including:
Patients may experience a lack of clarity of vision and difficulty concentrating when looking at distant or near objects, which may interfere with daily visual activities such as reading, driving, and fine maneuvers.
Some patients have increased sensitivity to light, and may feel harsh or uncomfortable even in normal light, and even need to wear sunglasses in bright light environments to reduce discomfort. These vision problems may require treatment adjustments or other measures to alleviate them.
Patients should remain vigilant in the face of visual problems in Balversa treatment, such as blurring, light sensitivity, etc. As soon as symptoms develop, you should seek medical attention and inform your doctor so that you can take countermeasures, such as adjusting the dose or stopping the medication.
If you have visual problems during the use of Balversa, you can take the following two countermeasures:
Visual symptoms such as blurred vision and light sensitivity should be reported immediately so that the doctor can assess the severity of the symptoms and adjust the treatment plan, such as lowering the dose of medication or changing it.
When outdoors, wear sunglasses with UV protection to reduce light irritation; Avoid prolonged use of electronic devices, pay attention to eye hygiene, and take appropriate rest to reduce eye strain. Keep the room soft and avoid excessively strong or dark-light environments.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: